DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for juvenile myoclonic epilepsy — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleJuvenile myoclonic epilepsy maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for juvenile myoclonic epilepsy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cholinergic receptor nicotinic alpha 1 subunit (CHRNA1) — CHRNA1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet clrdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9DMS · 1.92 Å · ligand CHOLESTEROL (CLR). Experimental structure, not a prediction.
What the evidence adds up to
Juvenile myoclonic epilepsy is one of the most common epilepsies seen in adult clinics. Most patients have a good prognosis when treated with valproate, but a significant minority are more difficult to treat. A 2010 article outlines a management strategy for when the initial antiepileptic drug fails, but provides no quantitative data on response or survival.
A 2016 review notes that juvenile myoclonic epilepsy usually appears between ages 12 and 18. Half of patients have relatives with epilepsy. The genetic basis is complex, the mechanism of transmission unclear, and several different genes may be responsible. The review strongly suggests a heritable condition meriting further investigation, but gives no concrete numbers on outcomes.
A 2013 reappraisal of 66 patients followed for a mean of 44.6 years challenges the view that seizure relapse upon drug discontinuation is invariable. No response rates, survival figures, or drug-specific outcomes are reported in any of these abstracts.
What is still missing: prospective trials with clearly defined endpoints, quantitative data on treatment failure rates, and genetic stratification to identify which patients might benefit from alternatives to valproate. No funding for such trials is mentioned.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Disease in Childhood · 1988 · 39 citations · open access
Juvenile myoclonic epilepsy.
AbstractThe clinical and electroencephalographic features of 10 adolescents with juvenile myoclonic epilepsy are presented. The mean age on onset was 12.3 years. Myoclonic jerks, predominantly on awakening, occurred in all 10 and were associated with infrequent generalised tonic-clonic seizures in nine. Five had first degree relatives with seizures. The neurodevelopmental status was normal in eight and social integration good in seven. Waking interictal electroencephalograms showed normal background activity in nine, polyspike and wave in six, and single spike and wave in eight. Four were photosensitive. Failure to respond to other antiepileptic drugs was usual, but valproate monotherapy resulted in good or complete seizure control. Juvenile myoclonic epilepsy is a well defined clinical entity that responds well to valproate and is usually associated with a good outlook.
When the first antiepileptic drug fails in a patient with juvenile myoclonic epilepsy
AbstractJuvenile myoclonic epilepsy is one of the most common types of epilepsy seen in an adult epilepsy clinic. Most patients have a good prognosis, particularly when treated with valproate, but a significant minority are more difficult to treat. In this article, we will focus on a management strategy when the initial antiepileptic drug is unsuccessful and outline an approach that translates directly to the clinic.
Epilepsy and Paroxysmal Conditions · 2016 · 10 citations · open access
CLINICAL AND GENETIC HETEROGENITY OF JUVENILE MYOCLONIC EPILEPSY
AbstractThe idiopathic generalized epilepsies constitute roughly one-third of all epilepsies. Juvenile myoclonic epilepsy (Janz syndrome) is characterized by myoclonic jerks on awakening, generalized tonic-clonic seizures, and typical absences, with the latter occurring in more than one-third of the patients. However, typical absences are not the predominant seizure type, and are usually very mild and simple (with no automatisms or localized limb jerks). Juvenile myoclonic epilepsy usually appears in adolescents between 12 and 18 years old. Half of patients with this condition have relatives with epilepsy. The genetic basis of this syndrome is complex and the mechanism of transmission is unclear. It is possible that several different genes are responsible. The authors presented the review of results modern clinical and genetic studies of juvenile myoclonic epilepsy. Information obtained from this review strongly suggests a heritable condition that merits further investigation.
Comment: A reappraisal of juvenile myoclonic epilepsy
AbstractThe education of neurologists on the syndrome of juvenile myoclonic epilepsy (JME) has been one of the major successes in the treatment of epilepsy. For a long time, the original author to whom this condition is eponymously linked, as well as other experts, conceived of JME as a lifelong condition in which seizure relapse upon drug discontinuation is invariable. This report by Senf et al. on a group of 66 patients with JME followed for a mean of 44.6 years gives a reappraisal of several aspects of the condition.1
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
